The selective i-20S inhibitor carfilzomib has shown clinical activity in vitro in primary CD34+ PMF cells and it is safe in combination with ruxolitinib in patients affected by several hematological malignancies (clinical trial.gov, NCT03773107), suggesting that targeting IPs is worth being investigated in PMF. Here, CD34 is linked to hematologic disorder.